|
Correlation of circulating EBV-targeted cytotoxic T lymphocyte precursors (EBV-CTLp) and clinical response following tabelecleucel (tab-cel) infusion in patients with EBV-driven disease. |
|
|
Employment - Atara Biotherapeutics |
Stock and Other Ownership Interests - Atara Biotherapeutics |
Patents, Royalties, Other Intellectual Property - Atara Biotherapeutics |
|
|
Employment - Atara Biotherapeutics |
Stock and Other Ownership Interests - Atara Biotherapeutics |
Research Funding - Atara Biotherapeutics |
Patents, Royalties, Other Intellectual Property - Atara Biotherapeutics |
|
|
Employment - Atara Biotherapeutics |
Stock and Other Ownership Interests - Atara Biotherapeutics |
|
|
Employment - Atara Biotherapeutics |
Stock and Other Ownership Interests - Atara Biotherapeutics |
|
|
|
Stock and Other Ownership Interests - Loxo |
Honoraria - Atara Biotherapeutics |
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - HemOgenyx |
Consulting or Advisory Role - Actinium Medical Advisory Board; HemOgenyx; Juno Therapeutics; Tessa Therapeutics |
Research Funding - Atara Biotherapeutics; Fate Therapeutics; Juno Therapeutics; Miltenyi Biotec; Novartis |
|
|
Employment - Amgen; Atara Biotherapeutics |
Stock and Other Ownership Interests - Amgen; Atara Biotherapeutics |
|
|
No Relationships to Disclose |
|
|
Employment - Atara Biotherapeutics |
Stock and Other Ownership Interests - Atara Biotherapeutics; GE Healthcare; Kite, a Gilead company; Pfizer |
Patents, Royalties, Other Intellectual Property - Patent pending for a use of cytotoxic T lymphocytes (Inst) |
|
|
No Relationships to Disclose |